ENDRA Life Sciences Inc. (NASDAQ: NDRA), a leader in Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, proudly announced the issuance of three new patents on February 14, 2024, marking a significant milestone in the company's intellectual property expansion. These patents, awarded in the U.S., China, and Europe, elevate ENDRA's global patent portfolio to a total of 74 issued patents. This achievement underscores the company's dedication to advancing thermoacoustic technology and its potential to revolutionize clinical practices by providing innovative solutions for unmet clinical needs.

The newly issued patents bolster the TAEUS system's capabilities, enhancing its efficiency in surgical procedures and thermal ablation therapies. They focus on innovations that improve the system's ability to absorb maximum radiofrequency energy, reduce signal noise, and monitor temperature precisely. Such advancements are crucial for optimizing treatment parameters, minimizing damage to healthy tissues, and effectively targeting cancerous cells, ultimately leading to improved therapeutic outcomes and reduced side effects.

Michael Thornton, ENDRA's Chief Technology Officer, expressed pride in the company's expanding patent estate, noting the significance of such growth for a company of ENDRA's size. Thornton emphasized the company's ongoing commitment to protecting its novel TAEUS® technology in key markets worldwide through a robust intellectual property portfolio. He highlighted the potential of these technological advancements to address unmet clinical needs, further solidifying ENDRA's position as a frontrunner in the field of thermoacoustic systems.

The specifics of the patents include:

• U.S. Patent No. 11844650, titled "Thermoacoustic Measurement Probe," which introduces a novel sleeve-type structural configuration for the TAEUS system that optimizes radiofrequency energy absorption and enhances thermoacoustic signal clarity.
• Chinese Patent No. ZL2021800757024, titled "Thermal Ablation System with Integrated Thermoacoustic Temperature Measurement," which describes a system designed to precisely monitor temperature during thermal ablation procedures, ensuring the safety and efficacy of the treatment.
• European Patent No. EP3902490, titled "Method and System for Monitoring Tissue Temperature," which outlines a new method for monitoring tissue temperature during various surgical procedures, enhancing the safety and outcomes of thermotherapy and cryotherapy treatments.

These patents not only secure ENDRA's technological advancements but also pave the way for further innovation in the field of medical imaging and treatment, offering new possibilities for patient care and clinical excellence.